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www.cdatm.orgAbstractObjective: To evaluate whether stem cell transplantation improves global left ventricular ejection fraction (LVEF) in patients with
acute myocardial infarction (AMI), and to determine the appropriate stem cell therapy dose as well as the effective period after stem
cell transplantation for therapy.
Methods: A systematic literature search included Pubmed, MEDLINE, China National Knowledge Infrastructure (CNKI), Chi-
nese Biomedical Literature Database (CBM), and Cochrane Evidence-Based Medicine databases. The retrieval time limit ranged
from January 1990 to June 2016. We also obtained full texts through manual retrieval, interlibrary loan and document delivery
service, or by contacting the authors directly. According to our inclusion and exclusion criteria, data were extracted independently
by two evaluators. In case of disagreement, a joint discussion occurred and a third researcher was utilized. Data were analyzed
quantitatively using Revman 5.2. Summary results are presented as the weighted mean difference (WMD) with 95% confidence
intervals (CIs). We collected individual trial data and conducted a meta-analysis to compare changes in global left ventricular
ejection fraction (DLVEF) after stem cell therapy. In this study, four subgroups were based on stem cell dose (1  107 cells,
1 108 cells,1 109 cells, and1 1010 cells) and three subgroups were based on follow-up time (<6 months, 6e12 months,
and 12 months).
Results: Thirty-four studies, which included 40 randomized controlled trials, were included in this meta-analysis, and 1927 pa-
tients were evaluated. Changes in global LVEF were significantly higher in the stem cell transplantation group than in the control
group (95% CI: 2.35e4.26%, P < 0.01). We found no significant differences in DLVEF between the bone marrow stem cells
(BMCs) group and control group when the dose of BMCs was1 107 [DLVEF 95% CI: 0.12e3.96%, P¼ 0.04]. The DLVEF in
the BMCs groups was significantly higher than in the control groups when the dose of BMCs was 1  108 [DLVEF 95% CI:
0.95e4.25%, P¼ 0.002] and1 109 [DLVEF 95%CI: 2.31e4.20%, P< 0.01]. In addition, when the dose of BMCs was between
109 and 1010 cells, we did not observe any significant differences [DLVEF 95% CI: 0.99e11.82%, P ¼ 0.10]. Our data suggest
stem cell therapy improves cardiac function in AMI patients when treated with an appropriate dose of BMCs.* Corresponding author.
E-mail address: rchuang@dlmedu.edu.cn (R.-C. Huang).
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Coronary heart disease is the number one cause of
death in China. Acute myocardial infarction (AMI) is
an important factor that predicts increased mortality
and heart failure incidence. Although modern thera-
peutics such as optimal drug treatment, percutaneous
coronary intervention (PCI), and coronary artery
bypass lower patient mortality and improve long-term
prognosis, infarcted cells cannot be recovered. As a
result, myocardial remodeling ensues and results in
heart failure. Therefore, recent studies regarding the
treatment of myocardial infarction have focused on
how to repair infarcted cells and reduce myocardial
remodeling to improve post-infarction heart function.
It has been demonstrated that stem cell trans-
plantation can significantly improve post-AMI systolic
and diastolic function, as well as decrease the severity
of necrocytosis and apoptosis in animal hearts, thereby
resulting in decreased mortality in experimental
animals.1 Moreover, clinical studies have found that
stem cell transplantation can improve post-infarction
left ventricular systolic and diastolic function.2,3
However, other studies have found that AMI patients
did not benefit from stem cell transplantation.4,5
Therefore, studies are currently evaluating efficacy is-
sues in stem cell transplantation using different types
of cells, different routes of transplantation, increased
cell doses, and the frequency of transfer.2,6,7 None-
theless, few reports have examined the optimal dose of
transferred cells that should be used.8,9 The present
meta-analysis was designed to investigate the impact
of various doses of stem cells on the heart function of
AMI patients to determine the optimal dose that should
be used in patients with AMI.
Materials and methods
Source of data and search strategy
We searched the electronic databases including
PubMed, MEDLINE, China National Knowledge
Infrastructure (CNKI), Chinese Biomedical Literature
Database (CBM), and Cochrane Evidence-basedmedicine databases using acute myocardial infarction
(AMI), stem cell, mononuclear stem cell, and percu-
taneous coronary intervention (PCI) as keywords. We
evaluated studies published from January 1990 to June
2016. We did not limit the language of the publication.
Alternatives included manual retrieval, interlibrary
loan, document delivery service, or contacting the
author directly.
Inclusion and exclusion criteria
We employed the following inclusion criteria: (1)
Randomized controlled trials (RCTs) with follow-up
times 3 months; (2) Patients clinically diagnosed
with AMI. The experimental group received both
percutaneous coronary intervention and autologous
bone marrow stem cells whereas the control group was
prescribed a standard medication regime; (3) Patients
in the experimental group received autologous bone
marrow stem cells via coronary arteries with no limit to
cell types or doses; (4) The outcome variable was left
ventricular ejection fraction (LVEF); (5) Chinese or
English publication language.
Exclusion criteria were the following: (1) Intrave-
nous or intramyocardial injection as the routes of stem
cell delivery; (2) Trials with no control group; (3)
Incomplete data (or no data) regarding stem cell dose;
or (4) Repeated studies on the same subjects.
Data extraction
All references were evaluated by two authors ac-
cording to the inclusion/exclusion criteria. Data were
extracted according to tables designed beforehand and
cross-checked. Disagreements were resolved by dis-
cussion between the authors and decided by a third
investigator, if necessary.
Statistical methods
We used the Revman 5.2 software package (The
Cochrane Collaboration, Copenhagen, Denmark) to
perform statistical analyses. Categorical data are pre-
sented as odds ratios with 95% confidence intervals
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differences (WMD) with 95% CIs. Subgroup analyses
were performed according to possible causative factors
of clinical heterogeneity, such as various stem cell doses.
Heterogeneity was examined using Q tests and I2 sta-
tistic. P < 0.1 was regarded as positive heterogeneity. I2
values between 0% and 40% were regarding as unim-
portant heterogeneity, 30e60% as moderate heteroge-
neity, 50e90% as significant heterogeneity, and
75e100% as massive heterogeneity. Homogeneous and
heterogeneous data were analyzed using the fixed effect
and random effect models, respectively.
Results
Literature search results
As shown in Fig. 1, 2505 articles were found using
computerized methods and an additional 102 were
identified by manual retrieval and interlibrary loan. Of
the 2607 total articles, 2260 were repetitive and
therefore excluded. The titles and abstracts of the
remaining 347 articles were read, and another 264 ar-
ticles were excluded. After reading the complete texts,Fig. 1. Flow diagram to illustrate the data collection and screening
processes. RCT: randomized controlled trials.49 articles did not meet the inclusion criteria and were
excluded. Ultimately, 34 articles containing 40 RCTs
were selected.
Material selection
We identified 40 RCTs.2e7,10e38 Our research var-
iables were differences in LVEF (DLVEF) before and
after follow-up in both the experimental and control
groups. Our meta-analysis included a total of 1927
patients (1037 in the experimental groups and 890 in
the control groups). Patient characteristics are shown in
Table 1.
Heterogeneity analyses
Heterogeneity was examined using I2 tests. With an
overall I2 > 50% in our study, heterogeneity existed
among the studies. A random effects model was used
for further analyses. In subgroup analyses, the sub-
group with a stem cell dose 1  107 had an I2 value
of 0%; therefore, a fixed effect model was used. The
heterogeneity in other subgroup analyses (including
different doses and follow-up durations) was 0, indi-
cating the population was non-heterogeneous.
Evaluation of DLVEF
Weighted-mean differences between pre- and post-
follow-ups were used as a summary statistic. DLVEF
in the experimental group was 3.31% (95%
CI: 2.35e4.26%, P < 0.01), which was higher than that
in control group (Fig. 2). This result suggests that stem
cell therapy may enhance the effect on LVEF based on
basic treatment in AMI patients.
The impact of different DLVEF doses in AMI patients
Table 2 shows that the 40 RCTs were divided into
four groups (stem cell doses 1  107, 1  108,
1  109, and 1  1010). Analyses of the correlation
between stem cell dose and changes in LVEF before
and after stem cell transplantation showed that AMI
patients who received stem cell therapy had higher
DLVEF values than control patients. The differences
were 2.04% (95% CI: 0.12e3.96%, P ¼ 0.04),
2.60% (95% CI: 0.95e4.25%, P ¼ 0.002), 3.25%
(95% CI: 2.31e4.20%, P < 0.01), and 5.41% (95%
CI: 0.99e11.82%, P ¼ 0.10), respectively (Fig. 2).
Therefore, our data indicate significant LVEF
improvement in AMI patients who received stem cell
therapy at a dose of 108e109 cells.
Table 1
The basic characteristics of included studies.
Investigator group Patients
(stem cell/control)
Change of LVEF (%) and 95% CI Dose of stem cell Time of stem cell
administration, d
Follow-up
time, month
Selection of
stem cell
Prepare of stem cell
administration
Experimental Control
Chen (2004) 34/35 18 (4.74) 6 (5.59) 8  109 18.4 6 BMSC DGS
Assmus (2002) 19/11 8.5 (6.44) 2.5 (6.37) 7.35  106 4.3 4 Not given DGS
Manginas (2007) 12/12 2.5 (4.95) 3.6 (5.59) 2e16  106 Not given 13 BMMC DGS
Hirsch (2010) 67/60 3.8 (7.4) 4 (5.8) 2.9 ± 1.6  108 3e8 4 BMMC DGS
Janssens (2006) 30/30 3.4 (6.9) 2.2 (7.3) 1.7 ± 0.7  108 1 4 BMSC DGS
Kang (2006) 25/25 5.1 (9.1) 0.2 (8.6) 1e2  109 3 6 PBSCs Spectrum acquisition
Meyer (2006) 30/30 6.7 (6.5) 0.7 (8.1) 2.4 ± 0.9  109 4.8 6 BMMC DGS
Quyyumi-HD (2011) 2/10 0.2 (0.8) 1 (7.8) 1.4 ± 0.2  107 8.3 6 BMMC DGS
Quyyumi-LD (2011) 4/10 0.02 (13) 1 (7.8) 4.8 ± 0.6  106 8.3 6 BMMC DGS
Quyyumi-MD (2011) 5/10 6.7 (4) 1 (7.8) 9.9 ± 0.7  106 8.3 6 BMMC DGS
Roman (2015) 26/24 6 (6) 4 (7) 6 (3.1e6.5)  107 3e5 12 BMMC DGS
Roncalli (2010) 47/44 1.9 (6.89) 2.2 (6,87) 1  108 9 3 Not given Unknown
Tendera-S (2009) 51/20 4.2 (14.5) 0.5 (9.08) 1.9  106 7 6 BMMC DGS
Tendera-U (2009) 46/20 4.4 (10.92) 0.5 (9.08) 1.78  108 7 6 BMMC DGS
Traverse (2010) 30/10 6.2 (9.8) 9.4 (10) 1  108 3e10 6 BMMC DGS
Wohrle (2010) 29/13 5.7 (8.4) 1.8 (5.3) 3.81 ± 1.3  108 5e7 6 BMMC DGS
Yao-DD (2009) 15/12 7.3 (3.43) 2.1 (1,71) 2.0 ± 1.4  108 3e7 3 BMMC DGS
Yao-SD (2009) 12/12 5.2 (2.72) 2.1 (1.71) 1.9 ± 1.2  108 3e7 3 BMMC DGS
Huang (2006) 20/20 3.3 (2.92) 1.2 (2.16) 1.8 ± 4.2  108 0.08 6 BMMC DGS
Huikun (2008) 36/36 7.1 (12.3) 1.2 (11.5) 4.0 ± 2.0  108 3 6 BMMC DGS
Schachinger (2006) 27/27 3.2 (6.8) 0.8 (6.8) 2.4 ± 1.7  108 3e6 4 BMMC DGS
Suarezdelzo (2007) 10/10 20 (8) 6 (10) 9  108 7 3 BMMC DGS
Su¨rder LD (2016) 42/55 0.7 (10.11) 1.9 (9.84) 1.395  108 24 12 BMMC DGS
Su¨rder SD (2016) 53/55 0.9 (10.50) 1.9 (9.84) 1.597  108 6 12 BMMC DGS
Cao (2008) 41/45 8.17 (2.33) 5.41 (2.43) 1.25e5.0  108 7 6 BMMC DGS
Meluzin-HD (2008) 22/22 5 (4.69) 2 (4.69) 0.9e2.0  108 6.8 6 BMMC DGS
Meluzin-LD (2008) 22/22 3 (4.69) 2 (4.69) 0.9e2.0  107 8.9 6 BMMC DGS
Ge (2006) 10/10 4.8 (6.76) 1.9 (4.14) 4  107 0.62 6 BMMC DGS
Huang (2007) 20/20 7.1 (3) 2.9 (2.6) 1.2 ± 6.5  108 1 6 BMMC DGS
Jin (2008) 14/12 4.28 (3.53) 0.28 (4.03) 6.3 ± 1.6  107 7e10 6 BMMC DGS
Karpov (2005) 16/10 6.3 (7.31) 4.9 (3.85) 8.8 ± 4.9  107 7e21 6 BMMC DGS
Li (2007) 35/23 7.1 (5.66) 1.6 (4.95) 7.2 ± 7.3  107 5 6 BMMC DGS
Lunde (2006) 50/50 3.1 (7.9) 2.1 (9.2) 0.68 (0.5e1.3)  108 4e8 6 BMMC DGS
Penicka (2007) 14/10 6 (5.41) 8 (4.03) 2.64  109 4e11 4 BMMC DGS
Piepoli (2010) 17/15 12 (5.28) 6.7 (6.44) 2.49  108 4 12 Not given Unknown
Plewka (2009) 38/18 9 (6.1) 5 (4.95) 1.44 ± 0.49  108 7 6 Not given DGS
You (2008) 7/16 13.3 (3.98) 4 (3.58) 7.5  107 14 2 BMSC DGS
Grajek (2010) 31/14 2.74 (7.07) 0.11 (6.47) 4.1 ± 1.8  108 4e6 6 Not given DGS
Nogueira-AG (2009) 14/6 5.5 (7.22) 0.48 (11.3) 1  108 5.5 6 BMMC DGS
Nogueira-VG (2009) 14/6 0.39 (6.39) 0.48 (11.3) 1  108 6 6 BMMC DGS
Data of dose of SC and time of SC administration are a separate number, range or mean±SD, depending on original data of the articles.
BMSC: bone marrow stem cell; BMMC: bone marrow mononuclear cell; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; HD: high dose; MD: medium dose; LD:
means low dose; S: selected BMSC; U: unselected BMSC; DD: double BMSC dose (first delivery: mean 2.0 (SE 1.4) 108, second delivery: mean 2.1 (SE 1.7) 108); SD: single BMSC dose (dose
of stem cells: mean 1.9 (SE 1.2)  108); AG: coronary artery route BMSC; VG: coronary venous route BMSC; DGS: density gradient separation.
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Fig. 2. Effects of stem cell dosage on LVEF. SD: standard deviation; SC: stem cell.
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Table 2
Number of patients and studies in groups of different stem cell doses.
Dose of
stem cell
Number
of study, n
Number of
patients (stem cell/control)
1  107 5 108/86
1  108 16 387/352
1  109 15 439/352
1  1010 4 103/100
Table 3
The mortality of included studies.
Investigator group Number of patients (stem cell/control) N
Chen (2004) 34/35 0
Assmus (2002) 19/11 0
Manginas (2007) 12/12 0
Hirsch (2010) 67/60 0
Janssens (2006) 30/30 1/
Kang (2006) 25/25 0/
Meyer (2006) 30/30 0
Quyyumi-HD (2011) 2/10 0
Quyyumi-LD (2011) 4/10 0
Quyyumi-MD (2011) 5/10 0
Roman (2015) 26/24 0
Roncalli (2010) 47/44 1/
Tendera-S (2009) 51/20 1/
Tendera-U (2009) 46/20 1/
Traverse (2010) 30/10 0
Wohrle (2010) 29/13 0
Yao-DD (2009) 15/12 0
Yao-SD (2009) 12/12 0
Huang (2006) 20/20 0
Huikun (2008) 36/36 0/
Schachinger (2006) 27/27 2/
Suarezdelzo (2007) 10/10 0
Su¨rder LD (2016) 42/55 1/
Su¨rder SD (2016) 53/55 3/
Cao (2008) 41/45 0
Meluzin-HD (2008) 22/22 0
Meluzin-LD (2008) 22/22 0
Ge (2006) 10/10 0
Huang (2007) 20/20 0
Jin (2008) 14/12 0
Karpov (2005) 16/10 0
Li (2007) 35/23 0
Lunde (2006) 50/50 0
Penicka (2007) 14/10 0
Piepoli (2010) 17/15 0
Plewka (2009) 38/18 2/
You (2008) 7/16 0
Grajek (2010) 31/14 1/
Nogueira-AG (2009) 14/6 0
Nogueira-VG (2009) 14/6 0
Note: BMSC: bone marrow stem cell; HD: high dose; MD: medium dose;
BMSC dose (first delivery: mean 2.0 (SE 1.4)  108, second delivery: mean
1.9 (SE 1.2)  108); AG: coronary artery route BMSC; VG: coronary veno
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Eleven studies reported deaths cases, in experi-
mental group, there were 13 death cases in total, 6
patients in control group (Table 3). The results showed
no significant statistical differences between the
experimental group and the control group (95% CI:
0.60e2.87%, P ¼ 0.50) (Fig. 4).umber of death (stem cell/control) Mortality (%)
Experimental Control
0 0
0 0
0 0
0 0
0 3.23 0
1 0 0
0 0
0 0
0 2.78
3.33 0
0 0
0 0 4.00
0 0 0
0 0 0
0 0
0 0
0 0
0 0
0 0
1 0 0
2 0 0
0 0
0 0 0
0 5.26 11.11
0 0
0 0
0 0
0 0
2.13 0
7.41 7.41
0 0
2.38 0
5.66 0
1.96 0
2.17 0
2 0 0
0 0
0 0 0
0 0
0 0
LD: low dose; S: selected BMSC; U: unselected BMSC; DD: double
2.1 (SE 1.7)  108); SD: single BMSC dose (dose of stem cells: mean
us route BMSC.
Fig. 3. Funnel plot of publication bias. SC: stem cell; MD: medium
dose.
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In our study, we examined publication bias using
a funnel plot. We found symmetrical distribution of
the included studies, suggesting acceptable publica-
tion bias in the studies used in our meta-analysis
(Fig. 3).
Discussion
Our study found improved LVEF in AMI patients
after stem cell therapy using a dose of 108e109 cells.
Stem cell therapy has been used in the treatment of
hematological malignances for more than 40 years.39
Multiple RCTs have assessed its safety and efficacy
in heart disease2,12,14,16,22,37 and reported that bone
morrow-derived stem cell transplantation may improveFig. 4. Mortality of stem cell transplantation.
LD: means low dose; S: selected bone marrow stem cell; U: unselected bon
1.9 (SE 1.2)  108).heart function without increasing the incidence of
adverse cardiac events in AMI patients.40 However,
compared with the 40% improvement in LVEF in an-
imal experiments,1 there is a lack of large-scale, long-
term, multi-center RCT data confirming these results.
Indeed, in several clinical studies, LVEF improvement
after autologous bone marrow-derived stem cells was
minimal and inconsistent. These results are likely
attributed to different types of subjects, methods of
bone marrow stem cell separation, transplanted stem
cell doses, timing of transplantation, and evaluation
methods.40,41 Bone marrow samples were collected
under sterile conditions from the iliac crest in local
anesthesia. The cell processing in most studies was
density gradient centrifugation. Moreover, few studies
have evaluated the relationship between cell dose and
LVEF. By analyzing the relationship between cell dose
and DLVEF, we found that as cell dose increases,
LVEF improves. In patients that received cell doses
1  107, although the differences were not signifi-
cant, there was a trend toward improved LVEF. Of the
40 included studies, 31 involved cell doses between
108 and 109. Results from these studies showed higher
DLVEF values in the cell transplantation groups
compared to control subjects. Using higher cell doses
(1  1010), DLVEF was higher in the experimental
groups than control groups, although the difference
was not statistically significant. If not acquired from
in vitro cultivation and amplification, large doses of
stem cells indicate a large amount of blood or bone
marrow is drawn from AMI patients themselves.
Therefore, it is often hard to secure such high doses of
stem cells and only four studies (including 103
experimental patients and 100 control patients) using
this dose range were included in this meta-analysis.e marrow stem cell; SD: single BMSC dose (dose of stem cells: mean
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and lead to bias in the final results.42 Other studies
have shown that DLVEF is 12.00% (95% CI:
9.56e14.44%) higher in the stem cell group.2 How-
ever, these results may be related to bone marrow
mesenchymal stem cells, which was transplanted in
this study. However, the source of stem cells is bone
marrow mononuclear cells in other studies.43
Because the majority of studies in this meta-
analysis used cell doses of 108e109, we further stud-
ied the short- and long-term impact of stem cells in this
dose range on the hearts of AMI patients. Most studies
lacked long-term consecutive data analyses on patients.
Most studies had follow-up periods less than 3 years.
Most studies considered short-term (~6 months) stem
cell therapy effective; however, in long-term evalua-
tions, the data are inconsistent regarding whether cell
transplantation improved heart function. Currently, few
follow-up studies have evaluated patients 18 months to
3 years after cell transplantation. Because it is impos-
sible to objectively evaluate these results, more studies
are warranted.
Many factors may have affected our meta-analysis
results. First, LVEF is a major variable to evaluate the
effect of stem cell therapy, and the methods were not
identical. Different methodologies for evaluating heart
function may have altered the results. Due to the small
sample size, our study was unable to investigate the
relationship between different heart function evaluation
methods and transplanted cell doses. As more RCTs are
published, future meta-analyses can be grouped ac-
cording to evaluationmethod and subgroup analyses can
be conducted to achieve more reliable results. More-
over, although the majority of included studies showed
benefits from stem cell therapy, nine studies suggested
no benefits or reported worse outcomes for transplanted
patients than controls.4,5,10,15,27,30 However, these data
may be attributed to the small sample size, which results
in large sampling errors and may alter the study
results.42
Second, DLVEF is not the only variable used to
evaluate heart function. Key factors involved in ven-
tricular remodeling and heart dysfunction include
myocardial necrosis and the absolute decrease in car-
diomyocyte number caused by myocardial ischemia
and reperfusion injury. Many studies, in addition to
DLVEF, also included left ventricular end diastolic
volume (LVEDV).17,18,25 However, there were insuffi-
cient LVEDV data to analyze statistically.
Third, the mortality data and report it either
numerically or in table format. Mortality data is absent
also important at the moment. Ventricular function isessential, but the change in mortality is crucially more
significant parameter, that also reveals any possible
adverse effect from cell transplantation. Such data is
usually poorly presented in these RCTs. Our study
found that the stem cells transplantation had not too
much influence on mortality.
Finally, the timing of transplantation may affect the
results. Some studies have confirmed that the timing of
stem cell introduction affects AMI patients. Immediately
after AMI (1e2 days), presumably due to significant
myocardial ischemia and inflammation, post-
reperfusion oxygen burst, and severe peroxidation
injury, there is increased local apoptosis of transplanted
stem cells. Thus, the efficacy of stem cell therapy is poor
early after AMI. Six to nine days after AMI, debris in the
heart is liquefied and absorbed. This process may also
influence survival of the surrounding infarct areas and
adversely affect transplanted stem cell survival and dif-
ferentiation. The microenvironment differs in various
pathological stages andmay affect transplanted stem cell
survival and differentiation. In clinical trials, the timing
of cell transplantation leads to different results. During
chronic and stable stages, the pathological environment
differs from the acute state and provides conditions for
transplanted stem cell growth and differentiation.
Therefore, most studies recommend transplantation 2e9
days after AMI.44 The earliest transplantation noted in
our meta-analysis was 2 hours after AMI and the longest
transplantation was 24 days after AMI. Therefore, this
large time span may affect the results of our study.
Although all included studies were RCTs, the total
sample size remained small, thereby resulting in an
inevitable bias in summary statistics. Thus, more RCTs
that focus on transplanted cell dose are warranted to
investigate the optimal stem cell dose for transplantation.
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